Thyroid Cancer | Topics

Cabozantinib Appears to be a Promising New Treatment Option in Radioiodine-Refractory Differentiated Thyroid Cancer
July 18, 2021

Results from the phase 3 COSMIC-311 trial indicated that cabozantinib elicited a promising survival benefit in patients with radioiodine-refractory differentiated thyroid cancer.

Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer
July 17, 2021

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer
June 08, 2021

Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.